{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T18:56:10Z","timestamp":1793213770278,"version":"4.5.0"},"reference-count":59,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T00:00:00Z","timestamp":1747785600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:p>Diabetic kidney disease (DKD) represents a leading complication of diabetes, frequently progressing to end-stage renal disease (ESRD), which significantly impairs patients\u2019 quality of life and imposes substantial healthcare burdens. Consequently, early detection and intervention in DKD are paramount. The incorporation of surrogate endpoints in clinical trials has emerged as a pivotal strategy for assessing the efficacy of novel therapies, facilitating the reduction of trial duration and associated costs. Currently, the rate of change in estimated glomerular filtration rate (eGFR) and urinary albumin excretion, either independently or in combination, serve as reliable surrogate endpoints for evaluating DKD progression. Although novel biomarkers such as KIM-1 and TNFR2 are not yet recommended as standalone surrogate endpoints for DKD, they hold potential when used in combination with established markers, such as eGFR slope and urinary albumin change rate, to improve the prediction of ESRD risk. While omics-based indicators demonstrate promise in DKD research, their utility requires further validation, particularly through long-term follow-up and dynamic monitoring, to establish their effectiveness and clinical applicability. Future research should prioritize the validation and optimization of potential surrogate endpoints through long-term follow-up studies and large-scale cohorts.<\/jats:p>","DOI":"10.3389\/fendo.2025.1557813","type":"journal-article","created":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T04:10:35Z","timestamp":1747800635000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Surrogate endpoints in diabetic kidney disease: current perspectives and future directions"],"prefix":"10.3389","volume":"16","author":[{"given":"Can","family":"Cao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiale","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tong","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Miao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiwei","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,5,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/nrneph.2015.173","article-title":"Changing epidemiology of type 2 diabetes mellitus and associated chronic kidney disease","volume":"12","author":"Thomas","year":"2016","journal-title":"Nat Rev Nephrol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2019.10.005","article-title":"Diabetic kidney diseases revisited: A new perspective for a new era","volume":"30","author":"Fu","year":"2019","journal-title":"Mol Metab"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.13355","article-title":"Changing epidemiology of chronic kidney disease as a result of type 2 diabetes mellitus from 1990 to 2017: Estimates from Global Burden of Disease 2017","volume":"12","author":"Li","year":"2021","journal-title":"J Diabetes Investig"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9040947","article-title":"GLP-1 receptor agonists and diabetic kidney disease: A call of attention to nephrologists","volume":"9","author":"G\u00f3rriz","year":"2020","journal-title":"J Clin Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1800256","article-title":"Risk factors, mortality, and cardiovascular outcomes in patients with type 2 diabetes","volume":"379","author":"Rawshani","year":"2018","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/nrneph.2013.146","article-title":"Nephrology in China","volume":"9","author":"Liu","year":"2013","journal-title":"Nat Rev Nephrol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1097\/MNH.0000000000000159","article-title":"Surrogate endpoints in clinical trials of chronic kidney disease progression: moving from single to multiple risk marker response scores","volume":"24","author":"Schievink","year":"2015","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"B8","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1067\/mcp.2001.113989","article-title":"Biomarkers and surrogate endpoints: preferred definitions and conceptual framework","volume":"69","year":"2001","journal-title":"Clin Pharmacol Ther"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.282034","article-title":"Clinical trial evidence supporting FDA approval of novel therapeutic agents, 2005-2012","volume":"311","author":"Downing","year":"2014","journal-title":"JAMA"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2014.07.030","article-title":"GFR decline as an end point for clinical trials in CKD: a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration","volume":"64","author":"Levey","year":"2014","journal-title":"Am J Kidney Dis"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2013.12.006","article-title":"GFR estimation: from physiology to public health","volume":"63","author":"Levey","year":"2014","journal-title":"Am J Kidney Dis"},{"key":"B12","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1053\/j.ajkd.2015.09.014","article-title":"GFR as the \u201cGold standard\u201d: estimated, measured, and true","volume":"67","author":"Levey","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2014040396","article-title":"Assessing the validity of surrogate outcomes for ESRD: A meta-analysis","volume":"26","author":"Jun","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2013.09.016","article-title":"Estimated GFR decline as a surrogate end point for kidney failure: a post hoc analysis from the Reduction of End Points in Non-Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan (RENAAL) study and Irbesartan Diabetic Nephropathy Trial (IDNT)","volume":"63","author":"Lambers Heerspink","year":"2014","journal-title":"Am J Kidney Dis"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.6634","article-title":"Decline in estimated glomerular filtration rate and subsequent risk of end-stage renal disease and mortality","volume":"311","author":"Coresh","year":"2014","journal-title":"JAMA"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2014.08.018","article-title":"GFR decline and subsequent risk of established kidney outcomes: a meta-analysis of 37 randomized controlled trials","volume":"64","author":"Lambers Heerspink","year":"2014","journal-title":"Am J Kidney Dis"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2014.08.019","article-title":"Utility and validity of estimated GFR-based surrogate time-to-event end points in CKD: a simulation study","volume":"64","author":"Greene","year":"2014","journal-title":"Am J Kidney Dis"},{"key":"B18","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1053\/j.ajkd.2019.06.009","article-title":"Change in albuminuria and GFR as end points for clinical trials in early stages of CKD: A scientific workshop sponsored by the national kidney foundation in collaboration with the US food and drug administration and European medicines agency","volume":"75","author":"Levey","year":"2020","journal-title":"Am J Kidney Dis"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2019010009","article-title":"Performance of GFR slope as a surrogate end point for kidney disease progression in clinical trials: A statistical simulation","volume":"30","author":"Greene","year":"2019","journal-title":"J Am Soc Nephrol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2019010008","article-title":"Evaluating glomerular filtration rate slope as a surrogate end point for ESKD in clinical trials: an individual participant meta-analysis of observational data","volume":"30","author":"Grams","year":"2019","journal-title":"J Am Soc Nephrol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2018.00693","article-title":"The evolving importance of insulin signaling in podocyte health and disease","volume":"9","author":"Lay","year":"2018","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B22","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1111\/dom.13969","article-title":"Pathophysiologic mechanisms in diabetic kidney disease: A focus on current and future therapeutic targets","author":"Barrera-Chimal","year":"2020","journal-title":"Diabetes Obes Metab"},{"key":"B23","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","article-title":"KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"105","year":"2024","journal-title":"Kidney Int Suppl"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2010.550","article-title":"Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease. A collaborative meta-analysis of kidney disease population cohorts","volume":"79","author":"Astor","year":"2011","journal-title":"Kidney Int"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2010.536","article-title":"Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts","volume":"79","author":"van der Velde","year":"2011","journal-title":"Kidney Int"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1007\/s10157-023-02328-y","article-title":"Changes in urinary albumin as a surrogate for kidney disease progression in people with type 2 diabetes","volume":"27","author":"Yokoyama","year":"2023","journal-title":"Clin Exp Nephrol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.2337\/dc17-1467","article-title":"Changes in albuminuria and the risk of major clinical outcomes in diabetes: results from ADVANCE-ON","volume":"41","author":"Jun","year":"2018","journal-title":"Diabetes Care"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(18)30313-9","article-title":"Change in albuminuria and subsequent risk of end-stage kidney disease: an individual participant-level consortium meta-analysis of observational studies","volume":"7","author":"Coresh","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1053\/j.ajkd.2021.02.335","article-title":"Changes in GFR and albuminuria in routine clinical practice and the risk of kidney disease progression","volume":"78","author":"Neuen","year":"2021","journal-title":"Am J Kidney Dis"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(19)30180-9","article-title":"Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial","volume":"7","author":"Mosenzon","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31150-X","article-title":"Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfac157","article-title":"Kidney outcomes with finerenone: an analysis from the FIGARO-DKD study","volume":"38","author":"Ruilope","year":"2023","journal-title":"Nephrol Dial Transplant"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2024.08.019","article-title":"A randomized, open-label, clinical trial examined the effects of canagliflozin on albuminuria and eGFR decline using an individual pre-intervention eGFR slope","volume":"106","author":"Miyamoto","year":"2024","journal-title":"Kidney Int"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.2337\/dc22-0382","article-title":"Dapagliflozin and prevention of kidney disease among patients with type 2 diabetes: post hoc analyses from the DECLARE-TIMI 58 trial","volume":"45","author":"Mosenzon","year":"2022","journal-title":"Diabetes Care"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.21474\/IJAR01\/6571","article-title":"Kim-1 and NGAL as biomarkers of nephropathy in type II diabetes","volume":"6","author":"Samia","year":"2018","journal-title":"Int J Adv"},{"key":"B38","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1053\/j.ajkd.2021.09.018","article-title":"Associations of plasma biomarkers of inflammation, fibrosis, and kidney tubular injury with progression of diabetic kidney disease: A cohort study","volume":"79","author":"Guti\u00e9rrez","year":"2022","journal-title":"Am J Kidney Dis"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-021-05512-5","article-title":"Effects of the SGLT2 inhibitor canagliflozin on plasma biomarkers TNFR-1, TNFR-2 and KIM-1 in the CANVAS trial","volume":"64","author":"Sen","year":"2021","journal-title":"Diabetologia"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.03530708","article-title":"Neutrophil gelatinase-associated lipocalin (NGAL) and progression of chronic kidney disease","volume":"4","author":"Bolignano","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"53","DOI":"10.4103\/ijn.IJN_96_17","article-title":"Neutrophil gelatinase-associated lipocalin: as a predictor of early diabetic nephropathy in type 2 diabetes mellitus","volume":"28","author":"Kaul","year":"2018","journal-title":"Indian J Nephrol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.2337\/dc10-1392","article-title":"Clinical significance of urinary liver-type fatty acid-binding protein in diabetic nephropathy of type 2 diabetic patients","volume":"34","author":"Kamijo-Ikemori","year":"2011","journal-title":"Diabetes Care"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1007\/s11255-023-03532-1","article-title":"Association of urinary liver-type fatty acid-binding protein with renal functions and antihyperglycemic drug use in type 2 diabetic nephropathy patients","volume":"55","author":"Hirowatari","year":"2023","journal-title":"Int Urol Nephrol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2024.12.002","article-title":"Evaluations of metabolic and innate immunity profiles in subjects with familial hypercholesterolemia with or without subclinical atherosclerosis","volume":"132","author":"Bosco","year":"2025","journal-title":"Eur J Intern Med"},{"key":"B45","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1186\/s12944-024-02308-5","article-title":"Association between non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio (NHHR) and diabetic kidney disease in patients with diabetes in the United States: a cross-sectional study","volume":"23","author":"Pan","year":"2024","journal-title":"Lipids Health Dis"},{"key":"B46","doi-asserted-by":"publisher","first-page":"2789279","DOI":"10.1155\/2022\/2789279","article-title":"The correlation between microalbuminuria and thyroid nodules in type 2 diabetic mellitus","volume":"15","author":"Cao","year":"2022","journal-title":"Int J Endocrinol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2024.1361840","article-title":"Temporal alteration of serum bilirubin levels and its renoprotective effects in diabetic kidney disease: exploring the hormonal mechanisms","volume":"2022","author":"Cao","year":"2024","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1111\/liv.16005","article-title":"Acute hyperbilirubinemia determines an early subclinical renal damage: Evaluation of tubular biomarkers in cholemic nephropathy","volume":"44","author":"Scilletta","year":"2024","journal-title":"Liver Int"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2020040487","article-title":"Association of multiple plasma biomarker concentrations with progression of prevalent diabetic kidney disease: findings from the chronic renal insufficiency cohort (CRIC) study","volume":"32","author":"Schrauben","year":"2021","journal-title":"J Am Soc Nephrol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2014010012","article-title":"Effect of pentoxifylline on renal function and urinary albumin excretion in patients with diabetic kidney disease: the PREDIAN trial","volume":"26","author":"Navarro-Gonz\u00e1lez","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000369576","article-title":"Effects of tumor necrosis factor-\u03b1 on podocyte expression of monocyte chemoattractant protein-1 and in diabetic nephropathy","volume":"5","author":"Chung","year":"2015","journal-title":"Nephron Extra"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.08780621","article-title":"Association between TNF receptors and KIM-1 with kidney outcomes in early-stage diabetic kidney disease","volume":"17","author":"Waijer","year":"2022","journal-title":"Clin J Am Soc Nephrol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.2337\/dc13-1983","article-title":"Synergism between circulating tumor necrosis factor receptor 2 and HbA(1c) in determining renal decline during 5\u201318 years of follow-up in patients with type 1 diabetes and proteinuria","volume":"37","author":"Skupien","year":"2014","journal-title":"Diabetes Care"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.2147\/DMSO.S282166","article-title":"Potential role and excretion level of urinary transferrin, KIM-1, RBP, MCP-1 and NGAL markers in diabetic nephropathy","volume":"13","author":"Siddiqui","year":"2020","journal-title":"Diabetes Metab Syndr Obes"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1159\/000528918","article-title":"Urinary biomarkers of tubular health and risk for kidney function decline or mortality in diabetes","volume":"53","author":"Chen","year":"2022","journal-title":"Am J Nephrol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-012-2755-2","article-title":"A urinary peptide biomarker set predicts worsening of albuminuria in type 2 diabetes mellitus","volume":"56","author":"Roscioni","year":"2013","journal-title":"Diabetologia"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(20)30026-7","article-title":"Early detection of diabetic kidney disease by urinary proteomics and subsequent intervention with spironolactone to delay progression (PRIORITY): a prospective observational study and embedded randomised placebo-controlled trial","volume":"8","author":"Tofte","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2020.01.019","article-title":"Metabolomic markers of kidney function decline in patients with diabetes: evidence from the chronic renal insufficiency cohort (CRIC) study","volume":"76","author":"Kwan","year":"2020","journal-title":"Am J Kidney Dis"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-021-05584-3","article-title":"Urinary metabolite profiling and risk of progression of diabetic nephropathy in 2670 individuals with type 1 diabetes","volume":"65","author":"Mutter","year":"2022","journal-title":"Diabetologia"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1557813\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T04:10:35Z","timestamp":1747800635000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1557813\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,21]]},"references-count":59,"alternative-id":["10.3389\/fendo.2025.1557813"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2025.1557813","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,21]]},"article-number":"1557813"}}